Key result
Dabigatran therapy for 6 months significantly improved convenience and satisfaction scores compared to previous vitamin K antagonist use in patients with nonvalvular atrial fibrillation.
Why the study?
The study was conducted to analyze patient perceptions of anticoagulation with dabigatran over 6 months in nonvalvular atrial fibrillation patients previously treated with vitamin K antagonists.
Does dabigatran improve patient convenience and satisfaction compared to previous vitamin K antagonists in patients with nonvalvular atrial fibrillation?
Observational (n=659)
Yes
Does dabigatran improve patient convenience and satisfaction compared to previous vitamin K antagonists in patients with nonvalvular atrial fibrillation?
Switching from vitamin K antagonists to dabigatran in patients with nonvalvular atrial fibrillation significantly improves patient-reported convenience and satisfaction.
Perceptions of dabigatran convenience may aid counseling; leaves open effects on adherence or outcomes in nonvalvular AF.
Aim: To analyze the perception of anticoagulation with dabigatran in patients with nonvalvular atrial fibrillation previously treated with vitamin K antagonists over a 6-month period. Materials & methods: This is a prospective, noninterventional, noncontrolled, multicenter study. To assess patients’ perceptions, PACT-Q2 questionnaire was completed. Results: Six hundred and fifty nine patients (73.1 ± 9.4 years, CHA 2 DS 2 -VASc 3.6 ± 1.6) were included. At baseline, the convenience and satisfaction scores were 60.9 ± 24.9 and 49.9 ± 17.7, respectively. The scores significantly increased along the study. Convenience score was higher in males and in patients with low–moderate thromboembolic risk. Satisfaction score was higher in females. Only 8.0% of patients discontinued dabigatran (3.7% due to side effects). Conclusion: Convenience and satisfaction scores for nonvalvular atrial fibrillation patients treated with dabigatran at 6 months were significantly better than with previous vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
Barrios et al. (2020) conducted an observational in nonvalvular atrial fibrillation (n=659). Dabigatran vs. Previous vitamin K antagonists was evaluated on Convenience and satisfaction scores (PACT-Q2 questionnaire). Dabigatran therapy for 6 months significantly improved convenience and satisfaction scores compared to previous vitamin K antagonist use in patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: